A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer


Tas F., Guney N., Derin D., Aydiner A., Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.2, pp.156-160, 2008 (SCI-Expanded) identifier identifier identifier

Abstract

Background. Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients.